ES2173111T3 - Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos. - Google Patents

Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.

Info

Publication number
ES2173111T3
ES2173111T3 ES94903295T ES94903295T ES2173111T3 ES 2173111 T3 ES2173111 T3 ES 2173111T3 ES 94903295 T ES94903295 T ES 94903295T ES 94903295 T ES94903295 T ES 94903295T ES 2173111 T3 ES2173111 T3 ES 2173111T3
Authority
ES
Spain
Prior art keywords
fenserine
cognoscitive
medicines
disorders
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903295T
Other languages
English (en)
Inventor
Nigel H Greig
Arnold Brossi
Timothy T Soncraint
Harold W Holloway
Stanley I Rapoport
Setsu Iijima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2173111T3 publication Critical patent/ES2173111T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN METODO MEJORADO DE TERAPIA COLINOMIMETICA PARA DAÑOS DE CONOCIMIENTO ASOCIADOS CON EL ENVEJECIMIENTO Y LA ENFERMEDAD DE ALZHEIMER COMPRENDIENDO TRATAR A UN PACIENTE CON UNA CANTIDAD EFECTIVA DE FENSERINA O UNA SAL ACEPTABLE FARMACEUTICAMENTE Y SUS DERIVADOS.
ES94903295T 1992-11-23 1993-11-23 Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos. Expired - Lifetime ES2173111T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/980,399 US5409948A (en) 1992-11-23 1992-11-23 Method for treating cognitive disorders with phenserine

Publications (1)

Publication Number Publication Date
ES2173111T3 true ES2173111T3 (es) 2002-10-16

Family

ID=25527533

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94903295T Expired - Lifetime ES2173111T3 (es) 1992-11-23 1993-11-23 Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.

Country Status (11)

Country Link
US (1) US5409948A (es)
EP (1) EP0668763B1 (es)
JP (1) JP3778363B2 (es)
AT (1) ATE213411T1 (es)
AU (1) AU693428B2 (es)
CA (1) CA2149924C (es)
DE (1) DE69331605T2 (es)
DK (1) DK0668763T3 (es)
ES (1) ES2173111T3 (es)
PT (1) PT668763E (es)
WO (1) WO1994012176A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9806184A (pt) * 1997-07-09 2001-06-19 Axonyx Inibidores de butirilcolinesterase altamente seletivos para o tratamento e o diagnóstico da doença de alzheimer e demências
WO2003032827A1 (en) * 2001-08-03 2003-04-24 Robert Becker Method for reliable measurement in medical care and patient self monitoring
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20040024043A1 (en) * 2002-03-22 2004-02-05 Nigel Greig Method for treating cognitive disorders
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7897639B2 (en) * 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
EP1740172A4 (en) * 2004-03-19 2007-10-10 Axonyx Inc ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
WO2005089746A1 (en) * 2004-03-19 2005-09-29 Axonyx, Inc. Dosage titration for treatment of cognitive disorders
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
CA2508585A1 (en) * 2004-06-01 2005-12-01 Axonyx, Inc. Transdermal delivery system for treatment of cognitive disorders
US20050272804A1 (en) * 2004-06-08 2005-12-08 Axonyx, Inc Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
US20070167509A1 (en) * 2005-06-14 2007-07-19 Joseph Araujo Use of phenserine and analogs to treat behavioral problems and improve trainability
WO2008097546A2 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
RU2327480C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
CN101795683A (zh) * 2007-07-18 2010-08-04 科露西德医药品公司 用于促进警醒症的方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
EP2445877B1 (en) 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
CA2768356A1 (en) * 2009-07-17 2011-01-20 Allergan, Inc. Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
US20120225922A1 (en) * 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
EP3334425B1 (en) 2015-08-14 2020-12-16 QR Pharma Methods of treatment or prevention of acute brain or nerve injuries
US10111860B1 (en) 2016-01-15 2018-10-30 Aristea Translational Medicine Corporation Compositions and methods for treating concussion
US10864192B2 (en) 2016-01-15 2020-12-15 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
CA3083015A1 (en) 2017-05-24 2018-11-28 Qr Pharma, Inc. Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans
WO2025017530A1 (en) 2023-07-19 2025-01-23 Assia Chemical Industries Ltd. Solid state forms of buntanetap and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US479107A (en) * 1892-07-19 oesterreich
US4791107A (en) * 1986-07-16 1988-12-13 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use
DE3843239C1 (es) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US4971992A (en) * 1989-03-27 1990-11-20 Hoechst-Roussel Pharmaceuticals Inc. Carbonate derivatives of eseroline
US4996201A (en) * 1989-08-02 1991-02-26 Warner-Lambert Co. 4-(N-substituted amino)-2-butynyl-1-carbamates and thiocarbamates and derivatives thereof as centrally acting muscarinic agents
US4914102A (en) * 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
US5077289A (en) * 1989-11-30 1991-12-31 Hoechst Roussel Pharmaceuticals Inc. Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine
US5171750A (en) * 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase

Also Published As

Publication number Publication date
AU5729094A (en) 1994-06-22
WO1994012176A1 (en) 1994-06-09
CA2149924C (en) 2006-01-31
DE69331605T2 (de) 2002-10-31
PT668763E (pt) 2002-08-30
DE69331605D1 (de) 2002-03-28
CA2149924A1 (en) 1994-06-09
EP0668763B1 (en) 2002-02-20
US5409948A (en) 1995-04-25
DK0668763T3 (da) 2002-06-03
EP0668763A1 (en) 1995-08-30
AU693428B2 (en) 1998-07-02
JPH08505130A (ja) 1996-06-04
ATE213411T1 (de) 2002-03-15
JP3778363B2 (ja) 2006-05-24

Similar Documents

Publication Publication Date Title
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
AU2807689A (en) Method for the treatment of body tissues and the administration of drugs thereto
AU3401093A (en) Therapeutic agent for threatened abortion
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
BR9406865A (pt) Uso de um sal farmaceuticamente aceitável de ropivacaina na fabricaçao de um produto farmaceutico processo para o tratamento de uma pessoa necessitando de alivio da dor e preparaçao farmaceutica
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
RU93050675A (ru) Способ коррекции психофизиологического состояния человека
FI953622L (fi) Ifenprodiilin ja sen diastereoisomeerien käyttö lääkeaineiden valmistukseen, jotka lääkeaineet ovat käyttökelpoisia perifeeristen neuropatiatilojen ja keskushermoston degeneratiivisten sairauksien hoitoon
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
MY112888A (en) Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases.
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
ITMI941939A0 (it) Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 668763

Country of ref document: ES